Scotiabank analyst George Farmer maintains $Syndax Pharmaceuticals (SNDX.US)$ with a hold rating, and maintains the target price at $18.
According to TipRanks data, the analyst has a success rate of 48.8% and a total average return of 9.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Syndax Pharmaceuticals (SNDX.US)$'s main analysts recently are as follows:
The FDA's approval of Revuforj has dissipated prior concerns surrounding the three-month extension. The implementation of a boxed warning for differentiation syndrome on Revuforj is anticipated to be consistent across the broader menin-inhibitor class, thus not posing a competitive disadvantage.
The approval of REVUFORJ, revumenib, for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients was granted by the FDA six weeks prior to the anticipated PDUFA date. The safety and efficacy indications are largely in line with expectations. Additionally, the recommendation for initial QTc monitoring with treatment is viewed as not being burdensome.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
豐業銀行分析師George Farmer維持$Syndax Pharmaceuticals (SNDX.US)$持有評級，維持目標價18美元。
根據TipRanks數據顯示，該分析師近一年總勝率為48.8%，總平均回報率為9.9%。
此外，綜合報道，$Syndax Pharmaceuticals (SNDX.US)$近期主要分析師觀點如下：
美國食品和藥物管理局對Revuforj的批准消除了先前對延期三個月的擔憂。預計在Revuforj上實施的分化綜合徵方框警告將在更廣泛的男性抑制劑類別中保持一致，因此不會構成競爭劣勢。
美國食品藥品管理局在預期的PDUFA日期前六週批准了REVUFORJ，即revumenib，用於成人和兒科患者復發或難治性急性白血病，並伴有 KMT2A 易位。安全性和有效性適應症基本符合預期。此外，建議通過治療進行初步的QtC監測被認爲並不繁重。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
